MG Stock Recent News
MG LATEST HEADLINES
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Mistras Group, Inc. (NYSE:MG ) Q4 2024 Earnings Conference Call March 6, 2025 9:00 AM ET Company Participants Thomas Tobolski - Treasurer Manuel Stamatakis - Executive Chairman of the Board Natalia Shuman - President and Chief Executive Officer Edward Prajzner - Senior Executive Vice President and Chief Financial Officer Conference Call Participants John Franzreb - Sidoti & Company Mitchell Pinheiro - Sturdivant & Company Operator Thank you for joining MISTRAS Group's Conference Call for its Fourth Quarter and Fiscal Year ending December 31, 2024. My name is Tanya and I'll be your event manager today.
Full year 2024 Revenue Growth of 3.4%, Net Income increased 208.6% to $19.0 million Full year 2024 Adjusted EBITDA (non-GAAP) of $82.5 million, an increase of 25.3% Full year 2024 Net Cash from Operations of $50.1 million, an increase of 87.4%; Free Cash Flow (non-GAAP) of $27.1 million, an increase of 775.9% Full year 2024 Selling, General and Administrative expenses decreased $10.4 million or 6.2% PRINCETON JUNCTION, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its fourth quarter and twelve months ended December 31, 2024.
PRINCETON JUNCTION, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, March 6, 2025 at 9:00 am Eastern Time to present its results for the fourth quarter and fiscal year ended December 31, 2024. A press release with the fourth quarter results will be issued after the close of market on Wednesday, March 5, 2025.
PRINCETON JUNCTION, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of MISTRAS Group, Inc. (NYSE: MG) is deeply saddened to announce the passing of Dr. Sotirios J. Vahaviolos, the company's Founder, Chairman Emeritus, and Board Director, on Thursday, February 6, 2025.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.